MedTrace Logo

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Sprinkle Study

NCT01282814 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-03-08

Study results available
· View outcomes & findings →

Summary

The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg capsules (test) versus Effexor® XR (reference) administered as the content of 1 x 150 mg extended-release capsule mixed with applesauce under fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Venlafaxine Hydrochloride

150 mg Extended-Release Capsule

DRUG

Effexor® XR

150 mg Extended-Release Capsule

Sponsors & Collaborators

  • Teva Pharmaceuticals USA

    lead INDUSTRY

Principal Investigators

  • Benoit Girard, M.D. · Anapharm

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2003-03-31
Completion
2003-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282814 on ClinicalTrials.gov